|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viewport
Window
×
×
×
TEDCO’s strategic plan, The Time, Talent, and Treasure Imperative for Maryland’s Ecosystem (T3IME), seizes this moment to build upon past successes and move forward differently than we have in the past. Specifically, we must scale significantly, and expand the type of resources over the next ten years (FY23-FY33). We must ensure that in this growth, we expand and include those that have been historically excluded. We will achieve this not only with market-based fiscal returns but also by curating, investing, and growing to scale enterprises that drive societal change for our citizens and the world.
Image: https://www.tedcomd.com
The GW TCO SBIR Matching Fund will help startups collaborate with GW researchers to develop innovations licensed from GW.
The first awards will be available in summer 2022. Applications from startups will be considered on a rolling basis and may now be submitted.
The GW TCO SBIR Matching Fund will provide up to $100K per award for internal GW research. It will match 2:1 the amount of research the applicant company has sponsored at GW in the last 2 years. Also included in the match are amounts the company is providing to GW as a subaward on a Phase I SBIR or STTR, which started in the last 2 years. The maximum award is $100,000. The scope of work is to further develop a technology licensed from GW TCO. Up to 2 GW TCO SBIR Matching Funds will be provided per fiscal year.
Image: https://commercialization.gwu.edu
Y Combinator, one of the biggest startup incubator in the world, has issued an unprecedented stark warning to their startup founders.
“No one can predict how bad the economy will get, but things don’t look good,” it said, before ordering entrepreneurs to tighten their belt, lean up, and try to just survive for the next two years without any further funds.
Image: Y Combinator’s Paul Graham addressing startup founders, 2020
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.
To sign-up for any of the EIR dates in 2022, please follow this link.
The Advanced Regenerative Manufacturing Institute (“ARMI”) is focused on empowering the U.S. regenerative medicine industry to bring new life-saving products to market by lowering the barriers to manufacturing. Our goal is to improve lives by restoring or replacing the function of damaged cells, tissues, and organs for patients. BioFabUSA’s mission is to develop a highly diverse, competitive, capable and innovative cell, tissue, and organ ecosystem that ensures a low-cost and high-quality domestic healthcare system, and domestic leadership in the biofabrication industrial base.
If I asked you, “Where in the United States is biotechnology innovation occurring at a record pace, what states or cities come to mind? You probably thought of Boston, San Francisco, or even New York immediately.
These are not bad guesses, but what if I told you that the Washington, D.C./Maryland/Virginia (DMV) region is one of the country’s best places to engage in the biotechnology sector?
Image: Courtesy of the National Cancer Institute (via Unsplash)
Working with rats, neuroscientists at Johns Hopkins University have pinpointed a mechanism in the brain responsible for a common type of age-related memory loss. The work, published in Current Biology, sheds light on the workings of aging brains and may deepen our understanding of Alzheimer’s disease and similar disorders in humans.
Image: https://hub.jhu.edu
Life sciences in New York City is poised for growth, but industry leaders said that will only be assured if developers build enough spaces for startups of all sizes. Unless the city can accommodate life sciences companies in their earlier years, when they need less space, experts warn NYC could lose talent to rival life sciences hubs.
Image: Bisnow/Ellie Meyer
Outshine Properties’ Bill Hunter, New York Economic Development Corp.’s Susan Rosenthal, Hunter Roberts Construction Group’s Brian Aronne, Nan Fung Life Sciences’ Matt Powers and SGA’s Brooks Slocum.
Dr. John Mumm explains the Diakine™ platform developed by Deka Biosciences.